Intensive blood-pressure control in patients with type 2 diabetes
Bi Y, Li M, Liu Y, et al.
N Engl J Med. Pub. online 16 Nov 2024.
Leggi
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease
Ostrominski JW, Højbjerg Lassen MC, Claggett BL, et al.
Eur Heart J. 2024:ehae780.
Leggi
Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab
Galderisi A, Sims EK, Evans-Molina C, et al.
Diabetologia. Pub. online 19 Nov 2024.
Leggi
Results from a randomized trial of intensive glucose management using CGM versus usual care in hospitalized adults with type 2 diabetes: the TIGHT study
Hirsch IB, Draznin B, Buse JB, et al.
Diabetes Care. 2024:dc241779.
Leggi
Alternative LDL cholesterol-lowering strategy vs high-intensity statins in atherosclerotic cardiovascular disease: a systematic review and individual patient data meta-analysis
Lee YJ, Hong BK, Yun KH, et al.
JAMA Cardiol. 2024:e243911.
Leggi
MODY Calculator and clinical features routinely used to distinguish MODY from type 2 diabetes in adults perform poorly for youth clinically diagnosed with type 2 diabetes
Kreienkamp RJ, Shields BM, Pollin TI, et al.
Diabetes Care. 2024:dc241565.
Leggi
Associations of clinical characteristics with sudden cardiac arrest in people with type 2 diabetes with and without cardiovascular disease: a longitudinal case-control study using routine primary care data
Harms PP, van Dongen LH, Bennis F, et al.
Diabetes Care. 2024:dc240715.
Leggi
Tirzepatide for heart failure with preserved ejection fraction and obesity
Packer M, Zile MR, Kramer CM, et al.
N Engl J Med. Pub. online 16 Nov 2024.
Leggi
Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction
Abdel Jawad M, Spertus JA, Ikeaba U, et al.
JAMA Cardiol. Pub. online 18 Nov 2024.
Leggi
Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial
Chimura M, Wang X, Jhund PS, et al.
JAMA Cardiol. 2024:e244613
Leggi